

RECEIVED
MAY 10 2002

TECH CENTER 1600/2900

U.S. DEPT. OF COMMERCE
PATENT & TRADEMARK OFFICE
MAY 07 2002

Sheet 1 of 5

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(MODIFIED) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Use several sheets if necessary)

(37 CFR §1.98(b))

Attorney Docket No. 06132/037002
Serial No. 10/039,183
Applicant Kleanthous et al.
Filing Date January 3, 2002
Group Not Yet Assigned
IDS Filed May 3, 2002
Customer No. 21559

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
[Signature]	5,116,821	05/26/92	Randall et al.			
	5,128,140	07/07/92	Chapura et al.			
	5,258,178	11/02/93	Cordle et al.			
	5,447,923	09/05/95	Catrenich et al.			
	5,476,669	12/19/95	Borody			
	5,514,660	05/07/96	Zopf et al.			
	5,538,729	07/23/96	Czinn et al.			
	5,563,039	10/08/96	Goeddel et al.			
	5,567,594	10/22/96	Calenoff			
	5,610,060	03/11/97	Ward et al.			
	5,620,964	04/15/97	Roth et al.			
	5,679,769	10/21/97	Danishesky et al.			
	5,753,630	05/19/98	Zopf et al.			
	5,837,240	11/17/98	Lee et al.			
	5,972,336	10/26/99	Michetti et al.			
[Signature]	6,290,962 B1	09/18/01	Michetti et al.			


EXAMINER

DATE CONSIDERED

6/7/00

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED
MAY 10 2002



Sheet 2 of 5

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	06132/037002
		Serial No.	10/039,183
		Applicant	Kleanthous et al.
		Filing Date	January 3, 2002
		Group	Not Yet Assigned 1645
		IDS Filed	May 3, 2002
		Customer No.	21559

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION


Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
WO 91/09049	27.06.91	PCT			
WO 93/18150	16.09.93	PCT			
WO 94/09823	11.05.94	PCT			
WO 95/22987	31.08.95	PCT			
WO 95/33482	14.12.95	PCT			
WO 96/33732	31.10.96	PCT			
WO 96/38475	05.12.96	PCT			
WO 96/40893	19.12.96	PCT			
WO 97/03359	30.01.97	PCT			
WO 97/03360	30.01.97	PCT			
WO 97/19098	29.05.97	PCT			
WO 97/11182	27.03.97	PCT			
WO 97/12908	10.04.97	PCT			
WO 97/12909	10.04.97	PCT			
WO 97/37044	09.10.97	PCT			
WO 98/18323	07.05.98	PCT			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

RECEIVED



Sheet 3 of 5

SUBSTITUTE FORM PTO-1449, U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT & TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR §1.98(b))		Attorney Docket No. 06132/037002 Serial No. 10/039,183 Applicant Kleanthous et al. Filing Date January 3, 2002 Group Not Yet Assigned 1645 IDS Filed May 3, 2002 Customer No. 21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
✓	Borén et al., "Attachment of <i>Helicobacter pylori</i> to Human Gastric Epithelium Mediated by Blood Group Antigens," Science 262:1892-1895 (1993).	
	Borody et al., "Omeprazole Enhances Efficacy of Triple Therapy in Eradicating <i>Helicobacter pylori</i> ," Gut 37:477-481 (1995).	
	Clayton et al., "Sensitive Detection of <i>Helicobacter pylori</i> by Using Polymerase Chain Reaction," Journal of Clinical Microbiology 30:192-200 (1992).	
	Czinn et al., "Oral Immunization Against <i>Helicobacter Pylori</i> ," Infection and Immunity 59:2359-2363, 1991.	
	Doig et al., "Identification of Surface-Exposed Outer Membrane Antigens of <i>Helicobacter pylori</i> ," Infection and Immunity 62:4526-4533 (1994).	
	Drouet et al., "Partial Characterization of an External Polysaccharide of <i>Helicobacter pylori</i> by Using an Immunoglobulin M Monoclonal Antibody," Infection and Immunity 61:2732-2736 (1993).	
	Fauchere et al., "Adherence of <i>Helicobacter pylori</i> Cells and Their Surface Components to HeLa Cell Membranes," Microbial Pathogenesis 9:427-439 (1990).	
	Ferrero et al., "Recombinant Antigens Prepared from the Urease Subunits of <i>Helicobacter</i> spp.: Evidence of Protection in a Mouse Model of Gastric Infection," Infection and Immunity 62:4981-4989 (1994).	
	Graham et al., "Effect of Triple Therapy (Antibiotics plus Bismuth) on Duodenal Ulcer Healing," Annals of Internal Medicine 115:266-269 (1991).	
	Haas et al., "TnMax- a Versatile Mini-Transposon for the Analysis of Cloned Genes and Shuttle Mutagenesis," Gene 130:23-31 (1993).	
	Husson et al., "Iron Acquisition by <i>Helicobacter pylori</i> : Importance of Human Lactoferrin," Infection and Immunity 61:2694-2697 (1993).	
	Illingworth et al., "Siderophore Production and Iron-Regulated Envelope Proteins of <i>Helicobacter pylori</i> ," Zbl. Bakt. 280:113-119 (1993).	
	Kaplan, "Autogenous Vaccination Against <i>Helicobacter pylori</i> ," South African Medical Journal 83:922-923 (1993).	
✓	Lee et al., "Oral Immunization with Recombinant <i>Helicobacter pylori</i> Urease Induces Secretory IgA Antibodies and Protects Mice from Challenge with <i>Helicobacter felis</i> ," The Journal of Infectious Diseases 172:161-172 (1995).	
EXAMINER		DATE CONSIDERED 6/7/05
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		

RECEIVED
MAY 10 2002
TECH CENTER 1600/200



Sheet 4 of 5

SUBSTITUTE FORM PTO 1216 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR §1.98(b))		Attorney Docket No.	06132/037002
		Serial No.	10/039,183
		Applicant	Kleanthous et al.
		Filing Date	January 3, 2002
		Group	Not Yet Assigned <i>1648</i>
		IDS Filed	May 3, 2002
		Customer No.	21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
<i>1648</i>	Mohammadi et al., "Helicobacter-Specific Cell-Mediated Immune Responses Display a Predominant Th1 Phenotype and Promote a Delayed-Type Hypersensitivity Response in the Stomachs of Mice," Journal of Immunology 156:4729-4738 (1996).		
	Monath et al., "Development of Recombinant <i>Helicobacter pylori</i> Urease as an Oral Vaccine: Current Status," Gut 37(Supp 1):A52 (1995).		
	Myers et al., "Oral Immunization with Recombinant Urease Confers Long-Lasting Immunity," Gut 39(Supp 2):A94 (1996).		
	Nakao et al., "Antibacterial Properties of Lansoprazole Alone and in Combination with Antimicrobial Agents against <i>Helicobacter pylori</i> ," Eur. J. Clin. Microbiol. Infect. Dis. 14:391-399 (1995).		
	Robinson et al., "Protection against a Lethal Influenza Virus Challenge by Immunization with a Haemagglutinin-Expressing Plasmid DNA," Vaccine 11:957-960 (1993).		
	Robinson et al., "Use of Direct DNA Inoculations to Elicit Protective Immune Responses," Vaccine 93, Cold Spring Harbor Laboratory Press, 311-315 (1993).		
	Sherburne et al., "Helicobacter pylori Expresses a Complex Surface Carbohydrate, Lewis X," Infection and Immunity 63:4564-4568 (1995).		
	Thijs et al., "Efficacy and Side Effects of a Triple Drug Regimen for the Eradication of <i>Helicobacter pylori</i> ," Scand. J. Gastroenterol. 28:934-938 (1993).		
	Tomb et al., "The Complete Genome Sequence of the Gastric Pathogen <i>Helicobacter pylori</i> ," Nature 388:539-547 (1997).		
	Ulmer et al., "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein," Science 259:1745-1749 (1993).		
<i>✓</i>	Wadstrom, "Microbial Adhesion: New Concepts for Development of Antiadhesion Strategies to Combat Bacterial Infections," Acta Microbiologica Hungarica 38:164-165 (1991).		
EXAMINER	<i>800</i>		DATE CONSIDERED <i>6/7/05</i>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

MAY 10 2002
ENTER 16

OTPE JC59
MAY 07 2002
TRADEMARK OFFICE

<p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p>	<p>Attorney Docket No. 06132/037002</p> <p>Serial No. 10/039,183</p> <p>Applicant Kleanthous et al.</p> <p>Filing Date January 3, 2002</p> <p>Group Not Yet Assigned 1645</p> <p>IDS Filed May 3, 2002</p> <p>Customer No. 21559</p>
--	--

[illegible]

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

6/7/05